scholarly journals Lysine clonixinate versus dipyrone (metamizole) for the acute treatment of severe migraine attacks: a single-blind, randomized study

2008 ◽  
Vol 66 (2a) ◽  
pp. 216-220 ◽  
Author(s):  
Abouch Valenty Krymchantowski ◽  
Henrique Carneiro ◽  
Jackeline Barbosa ◽  
Carla Jevoux
Keyword(s):  
Acute Treatment ◽  
Rescue Medication ◽  
International Headache Society ◽  
Randomized Study ◽  
Group 13 ◽  
Lysine Clonixinate ◽  
Inflammatory Drugs ◽  
Rectal Indomethacin ◽  
Single Blind ◽  
Severe Migraine

BACKGROUND AND OBJECTIVE: Nonsteroidal anti-inflammatory drugs (NSAID) are effective to treat migraine attacks. Lysine clonixinate (LC) and dipyrone (metamizol) have been proven effective to treat acute migraine. The aim of this study was to evaluate the efficacy and tolerability of the intravenous formulations of LC and dipyrone in the treatment of severe migraine attacks. METHOD: Thirty patients (28 women, 2 men), aged 18 to 48 years with migraine according the International Headache Society (IHS) (2004) were studied. The patients were randomized into 2 groups when presenting to an emergency department with a severe migraine attack. The study was single-blind. Headache intensity, nausea, photophobia and side effects were evaluated at 0, 30, 60 and 90 minutes after the drug administration. Rectal indomethacin as rescue medication (RM) was available after 2 hours and its use compared between groups. RESULTS: All patients completed the study. At 30 minutes, 0% of the dipyrone group 13% of the LC group were pain free (p=0.46). At 60 and 90 minutes, 2 (13%) and 5 (33%) patients from the dipyrone group and 11 (73%) and 13 (86.7%) patients from the LC group were pain free (p<0.001). At 60 minutes, significantly more patients from the LC group were nausea-free (p<0.001). Regarding photophobia, there were no differences between groups at 60 minutes (p=0.11). The use of RM at 2 hours did not differ among groups (p=0.50). Pain in the site of the injection was reported by more patients of the LC group compared to the dipyrone group (p<0.0001). CONCLUSION: LC is significantly superior to dipyrone in treating severe migraine attacks. LC promotes significantly more burning at the site of the injection.

scholarly journals Oral lysine clonixinate in the acute treatment of migraine: a double-blind placebo-controlled study

2001 ◽  
Vol 59 (1) ◽  
pp. 46-49 ◽  
Author(s):  
Abouch V. Krymchantowski ◽  
Jackeline S. Barbosa ◽  
Celia Cheim ◽  
Luiz A. Alves
Keyword(s):  
Placebo Group ◽  
Acute Treatment ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Pain Syndromes ◽  
Severe Intensity ◽  
Ihs Criteria ◽  
Lysine Clonixinate ◽  
Severe Migraine

Several oral nonsteroidal anti-inflammatory drugs (NSAIDs) are effective to treat migraine attacks. Lysine clonixinate (LC) is a NSAID derived from nicotinic acid that has proven to be effective in various pain syndromes such as renal colic and muscular pain. The aim of this double-blind, placebo-controlled study was to evaluate the efficacy of oral LC compared to placebo in the acute treatment of migraine. Sixty four patients with the diagnosis of migraine, according to the IHS criteria, were studied prospectively. Patients received LC or placebo once the headache reached moderate or severe intensity for 6 consecutive attacks. With regard to the moderate attacks, LC was superior than placebo after 1, 2 and 4 hours. The consumption of other rescue medications after 4 hours was significantly higher in the placebo group. With regard to the severe attacks, there was no difference between the active drug group and the placebo group concerning headache intensity and consumption of other rescue medications. We conclude that the NSAID lysine clonixinate is effective in treating moderately severe migraine attacks. It is not superior than placebo in treating severe migraine attacks.

Rizatriptan Combined with Rofecoxib Vs. Rizatriptan for the Acute Treatment of Migraine: an Open Label Pilot Study

Cephalalgia ◽  
2002 ◽  
Vol 22 (4) ◽  
pp. 309-312 ◽  
Author(s):  
AV Krymchantowski ◽  
JS Barbosa
Keyword(s):  
Side Effects ◽  
Acute Treatment ◽  
Rescue Medication ◽  
International Headache Society ◽  
Combination Group ◽  
Open Label ◽  
Group 2 ◽  
Fast Acting ◽  
Headache Recurrence ◽  
Group 1

Rizatriptan is an effective and fast acting drug for the acute treatment of migraine. As with any other acute treatment for migraine, headache recurrence may occur in up to one-third of responders. Combination with non-steroidal anti-inflammatory drugs (NSAIDs) seems to reduce the incidence of headache recurrence in clinical practice. Rofecoxib is a member of a new class of NSAIDs, which selectively inhibits the COX-2 enzyme and therefore is associated with a lower risk of gastrointestinal side-effects; the drug has a long plasma half-life (17 h). This open label study compared rizatriptan with rizatriptan plus rofecoxib in the acute treatment of migraine. Fifty-six triptan naive patients from a tertiary centre (37 women and 19 men, ages 16-55 years, mean 35 years) with International Headache Society migraine were randomized into two groups. They were instructed to treat three consecutive moderate or severe attacks with either 10 mg rizatriptan (group 1: 18 women and 10 men) or with 10 mg rizatriptan plus 25 mg rofecoxib (group 2: 19 women and 9 men). The presence of headache and nausea at 1, 2 and 4 h, and of side-effects, use of rescue medication and recurrence were compared. Fifty-four patients completed the study. Group 1 treated 76 attacks and group 2 treated 81 attacks. Absence of headache at 1 h was seen in 19 attacks (25%) in group 1 and in 34 attacks (42%) in group 2 ( P = 0.082); at 2 h absence of headache was seen in 60% of group 1 attacks and in 76% of group 2 attacks ( P = 0.115). At 4 h, 75% of group 1 attacks and 88% of group 2 attacks were pain free ( P = 0.122). With regard to nausea, of those who had nausea at baseline, 31% and 49% of attacks in groups 1 and 2, respectively, were nausea free at 1 h ( P = 0.091), 75% and 79% at 2 h ( P = 0.736) and 82% and 91% ( P = 0.479) at 4 h. Recurrence, based on all attacks of those patients who achieved pain free at 4 h, was observed in 53% of group 1 and 20% of group 2 attacks ( P< 0.001). Sustained pain- free rates (for the 4-h time point) were 45.6% of group 1 and 78.9% of group 2 attacks. There were no significant differences with regard to rescue medication consumption after 4 h and side-effects in both groups. There was a non-significant trend for the combination group to have a higher response rate. The group treated with rizatriptan and rofecoxib had a lower recurrence rate than the group treated with rizatriptan. This study demonstrated that combining a fast acting triptan such as rizatriptan with rofecoxib reduced headache recurrence rates, was well tolerated and may be more effective than the use of rizatriptan alone. Double-blind, placebo-controlled studies are necessary to confirm these observations.

Comparative Efficacy of Eletriptan vs. Naratriptan in the Acute Treatment of Migraine

Cephalalgia ◽  
2003 ◽  
Vol 23 (9) ◽  
pp. 869-876 ◽  
Author(s):  
G Garcia-Ramos ◽  
EA MacGregor ◽  
B Hilliard ◽  
CA Bordini ◽  
J Leston ◽  
...  
Keyword(s):  
Acute Treatment ◽  
Rescue Medication ◽  
International Headache Society ◽  
Double Blind Study ◽  
Comparative Efficacy ◽  
Free Response ◽  
Double Blind ◽  
Time Points ◽  
Ihs Criteria ◽  
Meta Analyses

This was a randomized, double-blind study designed to evaluate the comparative efficacy and tolerability of the 40-mg dose of eletriptan and the 2.5-mg dose of naratriptan. Patients ( n = 548) meeting International Headache Society (IHS) criteria for migraine were randomized to treat a single migraine attack with either eletriptan 40 mg, naratriptan 2.5 mg, or placebo. Headache response rates at 2 h and 4 h, respectively, were 56% and 80% for eletriptan, 42% and 67% for naratriptan ( P < 0.01 for both time-points vs. eletriptan), and 31% and 44% for placebo ( P < 0.0001 vs. both active drugs at both time-points). Eletriptan also showed a significantly greater pain-free response at 2 h (35% vs. 18%; P < 0.001) as well as lower use of rescue medication (15% vs. 27%; P < 0.01) and higher sustained headache response at 24 h (38%) compared with naratriptan (27%; P < 0.05) and placebo (19%; P < 0.01). Both eletriptan and naratriptan were well tolerated. The results confirm previous meta-analyses that have suggested the superiority of eletriptan vs. naratriptan in the acute treatment of migraine.

Metoclopramide as an Analgesic in Severe Migraine Attacks: An Open, Single-blind, Parallel Control Study

2011 ◽  
Vol 6 (2) ◽  
pp. 141-145 ◽  
Author(s):  
Gabriel Salazar ◽  
Marta Fragoso ◽  
Luis Vergez ◽  
Piera Sergio ◽  
Denisse Cuello
Keyword(s):  
Parallel Control ◽  
Single Blind ◽  
Severe Migraine ◽  
Control Study

Comparison of the renal effects of low to high doses of dopamine and dobutamine in critically ill patients: A single-blind randomized study

2000 ◽  
Vol 28 (4) ◽  
pp. 921-928 ◽  
Author(s):  
Carole Ichai ◽  
Jérôme Soubielle ◽  
M. Carles ◽  
Carine Giunti ◽  
Dominique Grimaud
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Randomized Study ◽  
Renal Effects ◽  
High Doses ◽  
Single Blind

scholarly journals The experience with repetitive peripheral magnetic stimulation in subjects with lumbosacral radiculopathy

2020 ◽  
Vol 10 (2) ◽  
pp. 31-38
Author(s):  
V. N. Blokhina ◽  
M. M. Kopachka ◽  
E. M. Troshina ◽  
D. S. Kanshin ◽  
S. G. Nikolaev
Keyword(s):  
Functional Status ◽  
Magnetic Stimulation ◽  
Randomized Study ◽  
Pain Syndrome ◽  
Duration Of Treatment ◽  
Traditional Treatment ◽  
Lumbosacral Radiculopathy ◽  
Significant Difference ◽  
Reduction Of Pain ◽  
Inflammatory Drugs

Introduction. Lumbosacral radiculopathy is а leading cause of long-term disability. Taking into a consideration the duration of treatment radiculopathy, the risk of developing adverse reactions when taking analgesics, non-steroidal anti-inflammatory drugs, the physiotherapeutic method — repetitive peripheral magnetic stimulation may become a promising method of therapy.Aim of the study. Assessment of the effectiveness of the complex treatment for patients with lumbosacral radiculopathy using the course of the repetitive peripheral magnetic stimulation.Materials and methods. Forty patients with lumbosacral radiculopathy were enrolled in the open non-randomized study, were divided into 2 parallel groups. The patients of the 1st group received a course of traditional treatment and a course of the repetitive peripheral magnetic stimulation. The patients of the 2nd group were treated with the traditional treatment without the course of the stimulation. A magnetic stimulator MagPro (Magventure, Denmark) was used for repetitive peripheral magnetic stimulation.Results. A significant difference (p <0.001) was registered regarding the reduction of pain syndrome and the improvement of the functional status after treatment in both groups. 14 (70 %) patients of the first group achieved a pain visual analogue scale relief by 50 % after 10 repetitive peripheral magnetic stimulation sessions, while 6 (30 %) patients did this after 15 repetitive peripheral magnetic stimulation sessions. We did not observed a statistically significant differences (p >0.05) in pain syndrome, functional status, anxiety level at the end of follow-up between the groups.Conclusion. We did not receive the benefits of the repetitive peripheral magnetic stimulation course in comparison with a traditional treatment of a lumbosacral radiculopathy. Further placebo-controlled studies to study the effect of repetitive peripheral magnetic stimulation on pain and anxiety in patients with back pain and radiculopathy are required.

Sumatriptan nasal spray for the acute treatment of migraine

Neurology ◽  
1997 ◽  
Vol 49 (5) ◽  
pp. 1225-1230 ◽  
Author(s):  
R. Ryan ◽  
A. Elkind ◽  
C. C. Baker ◽  
W. Mullican ◽  
S. DeBussey ◽  
...  
Keyword(s):  
Adverse Events ◽  
Migraine Attack ◽  
Nasal Spray ◽  
Acute Treatment ◽  
International Headache Society ◽  
Migraine Treatment ◽  
Multicenter Studies ◽  
Double Blind ◽  
Treatment Groups ◽  
Migraine Medication

Background: Sumatriptan nasal spray may be particularly useful for patients whose nausea and vomiting preclude them from using oral migraine medication or for patients who prefer not to use an injectable migraine medication. The objective of this study was to evaluate in two clinical studies the efficacy and tolerability of the intranasal form of sumatriptan in the acute treatment of a single migraine attack. International Headache Society-diagnosed adult migraineurs in two randomized, double-blind, parallel-group, multicenter studies (n = 409 and 436) used sumatriptan nasal spray 20 mg, 10 mg, or placebo (2:1:1) for the acute treatment of a single migraine attack at home. Predose and at predetermined postdose intervals, patients recorded headache severity (none, mild, moderate, severe); time to meaningful relief; clinical disability (none, mildly impaired, severely impaired, bed rest required); presence/absence of nausea, photophobia, and phonophobia; and the occurrence of adverse events. Two hours postdose in the two studies, moderate or severe baseline pain was reduced to mild or none in 62 to 63% of patients treated with sumatriptan 20 mg, 43 to 54% of patients treated with sumatriptan 10 mg, and 29 to 35% of placebo-treated patients (p < 0.05 20 mg versus placebo for both studies and 10 mg versus placebo for study 1). Onset of relief relative to placebo began as early as 15 minutes postdose(sumatriptan 20 mg, study 2). Clinical disability at 2 hours postdose was reported as mildly impaired or normal in 72 to 74% of patients treated with sumatriptan 20 mg, 56 to 68% of patients treated with sumatriptan 10 mg, and 47 to 58% of placebo-treated patients (p < 0.05 20 mg versus placebo for both studies). Similar efficacy rates were observed for nausea, photophobia, and phonophobia. The most common adverse event in the active treatment groups was disturbance of taste (bad, bitter, or unpleasant taste). Aside from this event, the pattern and incidence of adverse events did not differ among treatment groups. From these results we determined that sumatriptan nasal spray is a rapidly effective, well-tolerated migraine treatment. The 20-mg dose was effective in treating the entire migraine symptom complex, and the 10-mg dose was less consistently effective.

Single-Blind, Randomized Study Comparing Chromated Glycerin, Polidocanol Solution, and Polidocanol Foam for Treatment of Telangiectatic Leg Veins

2004 ◽  
Vol 30 (3) ◽  
pp. 367-372 ◽  
Author(s):  
Philippe Kern ◽  
Albert-Adrien Ramelet ◽  
Robert Wutschert ◽  
Henri Bounameaux ◽  
Daniel Hayoz
Keyword(s):  
Randomized Study ◽  
Single Blind
Sign in / Sign up

Export Citation Format

Share Document